In the setting of innate immunity, miR-122 directly targets TLR4 [89] which, in turn, triggers proliferation [90] and drug resistance of HCC cells through the COX-2/PGE2/STAT3 positive feedback loop [91]. Here, TLR4 is linked to hepatocellular carcinoma.